Hindun Wilda Risni

Hindun Wilda Risni

Auto-generated profile, based on publicly available information

Hindun Wilda Risni

University College London

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
VPVincent Pratama
Vincent Pratama
HRHindun Wilda Risni
Hindun Wilda Risni
EYEm Yunir
Em Yunir
RSRani Sauriasari
Rani Sauriasari
Pratama V, et al. Infect Chemother. 2022 Mar;54(1):125-139. https://doi.org/10.3947/ic.2021.0144

1 January 2023 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
MAMemy Aviatin
Memy Aviatin
RSRani Sauriasari
Rani Sauriasari
EYEm Yunir
Em Yunir
HRHindun Wilda Risni
Hindun Wilda Risni
Aviatin M, et al. Infect Chemother. 2023 Mar;55(1):80-89. https://doi.org/10.3947/ic.2022.0084

24 April 2026 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Open access
HRHindun Wilda Risni
Hindun Wilda Risni
LWLi Wei
Li Wei
MHMartha Hickey
Martha Hickey
LGLuke E Grzeskowiak
Luke E Grzeskowiak
JIJenni Ilomäki
Jenni Ilomäki
RBRuth Brauer
Ruth Brauer
Menopausal hormone therapy (MHT) is a mainstay treatment for menopausal symptoms. While international studies report rising MHT use, trends in Australia remain unclear. Using a 10% random sample of Pharmaceutical Benefits Scheme (PBS) data from 2014 to 2023, we analysed the prevalence of MHT dispensing among women aged 45–64. Overall prevalence of MHT dispensing remained stable (relative annual change: 0.42%, 95% CI −0.50 to 1.35). Use of transdermal and intrauterine device (IUD) MHT increased (5.89%, 95% CI 3.88–7.91 and 10.22%, 95% CI 9.48–10.95, respectively), and vaginal MHT decreased (−1.47%, 95% CI −2.30 to −0.63), while oral MHT appeared stable (0.66%, 95% CI −0.04 to 1.36). This study offers a clearer understanding of how MHT use in Australia has changed over the last decade.

1 April 2024 in Pharmacy Education
Verified
Journal Article
Open access
PDF file
RARetnosari Andrajati
Retnosari Andrajati
LKLarasati Arrum Kusumawardani
Larasati Arrum Kusumawardani
IAIsti Nurul Afifah
Isti Nurul Afifah
HRHindun Wilda Risni
Hindun Wilda Risni
Background: Ischemic stroke is one of the leading causes of death in Indonesia. Appropriate management, including the identification of drug-related problems (DRPs), is needed to prevent disability and death. Objective: This study aimed to analyse DRPs as defined by the Pharmaceutical Care Network Europe (PCNE). Method: This was a cross-sectional research using the medical records of in-patients with ischemic stroke aged >18 years. Result: Out of the 115 patients examined, 51.3% were male, and the mean age was 57.85 + 10.539 years. Exactly 204 cases of DRPs and 175 causes appeared in 101 patients. A total of 58 patients experienced one-to-two problems, and 43 patients experienced more than two problems. The problems domain consists of therapeutic effectiveness (P1, 133(65.2%)), adverse effects (P2, 67(32, 84%)), and medical expenses (P3, 4(1, 96%)). The DRPs mostly involved antihypertension and antiplatelet. The most common cause was a new indication for treatment (C1.9, 51(29.14%)) and drug interactions (C8.1, 48(27.43%)). Multivariate analysis of patient characteristics showed that patients taking more than eight medications were more likely to experience more than two DRPs than those on one-to-four medications (OR 5.593; 95%, CI 1.015-30.812). Conclusion: Most patients experienced one-to-two DRPs with the highest being a potentially suboptimal treatment. Clinical pharmacists are expected to monitor therapy, especially in polypharmacy patients.

1 April 2024 in Pharmacy Education
Verified
Journal Article
Open access
PDF file
ISIndana Ayu Soraya
Indana Ayu Soraya
RSRani Sauriasari
Rani Sauriasari
PPPukovisa Prawirohardjo
Pukovisa Prawirohardjo
HRHindun Wilda Risni
Hindun Wilda Risni
Background: Type II Diabetes Mellitus (T2DM) is a risk factor for decreased cognitive function that is rarely recognised by patients, apart from age and other factors. Objective: This study aims to assess the effect of decreased cognitive function on medication adherence in T2DM patients. Method: This study used a cross-sectional design conducted at the Pasar Minggu Community Health Center, Jakarta, Indonesia. Cognitive function was assessed using the validated Indonesian version of the Montreal Cognitive Assessment (MoCA-Ina) questionnaire. Results: One hundred twenty-seven T2DM patients (75.6% female) with a mean age of 58.69 years were recruited. The proportion of T2DM patients with decreased cognitive function was quite high, namely 61%. The proportion of non-adherent patients in the group with decreased cognitive function (70.6%) was greater than in the normal group (29.4%). Decreased cognitive function significantly affected non-adherence in taking medication with aOR 3.744 (95% CI 1.485–9.442), p = 0.005, after controlling for age, education level, HbA1c value, and comorbid dyslipidemia. Conclusion: Patients with decreased cognitive function are 3.7 times more likely to be non-compliant with medication, regardless of age, education level, HbA1c value, and dyslipidemia. Special management is needed for T2DM patients with decreased cognitive function, such as caregiver assistance, education by pharmacists, and simpler drug regimes.

25 June 2026 in Postgraduate Medicine
Verified
Journal Article
Open access
IZIlil Maidatuz Zulfa
Ilil Maidatuz Zulfa
HRHindun Wilda Risni
Hindun Wilda Risni
RBRuth Brauer
Ruth Brauer
CWCate Whittlesea
Cate Whittlesea
LWLi Wei
Li Wei
Calcium channel blockers (CCBs) and statins are commonly combined to prevent cardiovascular diseases (CVDs). However, their concomitant use may lead to drug-drug interactions (DDIs) and increased adverse effects (AEs). This systematic review and meta-analysis aimed to evaluate the evidence of adverse effects (AEs) associated with the calcium channel blockers (CCBs) and statins concomitant use. We searched MEDLINE, Embase, Web of Science, and CENTRAL from database inception to 4 April 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies reporting AEs of CCB-statin combinations compared with CCB or statin treatment in adults. Outcomes assessed included CCBs- and statins-associated AEs, treatment discontinuation, hospitalization, and all-cause mortality. Meta-analyses of similar outcomes were performed to estimate pooled Odds Ratios (OR) with 95% confidence intervals (CI). Of 9,737 articles screened, 20 studies (n = 1,053,198) were included. Peripheral edema, myalgia, and discontinuation were most reported in 11, 7, and 9 studies, respectively. Meta-analyses demonstrated no significant differences in the risk of peripheral edema (OR 1.03, 95% CI 0.14-1.48), myalgia (OR 1.33, 95% CI 0.63-2.79), or discontinuation (OR 0.78, 95% CI 0.50-1.23 for CCB-statin vs. CCB; OR 0.97, 95% CI 0.68-1.38 for CCB-statin vs. statin). However, evidence of other AEs was inconsistent and limited. CCB-statin combination appears generally safe in a short-term use (3 to 6 months). Further research is warranted to clarify the long-term risk of AEs.